Harvard Bioscience Inc. announced that its board has approved the spinoff of the company’s wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology Inc., known as HART. Harvard Bioscience will not own any shares of HART, which will be an independent public company. Harvard Bioscience makes a broad range of tools to advance life science research and regenerative medicine.
October 17, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢